Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Myeloma Immunotherapy
Research conducted at Harvard University has provided new information about myeloma immunotherapy
November 12th, 2008
Data detailed in 'Cellular immunotherapy for multiple myeloma' have been presented. According to recent research published in the journal Bailliere's Best Practice and Research In Clinical Haematology, "Multiple myeloma is a life-threatening haematological malignancy for which standard therapy is inadequate. Autologous stem cell transplantation results in effective cytoreduction, but patients subsequently relapse from sites of chemotherapy-resistant disease." "Allogeneic transplantation may result in durable responses due to anti-tumour immunity mediated by donor lymphocytes. However, morbidity and mortality related to graft-vs-host disease remains a challenge. A...
Source: Vaccine Weekly (2008-11-12)
|
